PropertyValue
?:definition
  • An orally bioavailable combination agent composed of the aldehyde dehydrogenase (ALDH) inhibitor NYH817G and the mitochondrial complex 1 (NADH-ubiquinone oxidoreductase) inhibitor NYH100P, with potential antineoplastic activity. Upon oral administration of ALDH inhibitor NYH817G and mitochondrial complex 1 inhibitor NYH100P, NYH817G targets and binds to ALDH, and prevents the formation of NADH. It also inhibits lactate dehydrogenase A (LDH-A), thereby preventing lactate formation from pyruvate. NYH100P targets and binds to MC1. This all blocks the cancer cell energy production pathway, deprives tumor cells of nutrients, and energy, and inhibits nucleotide and amino acid production, which induces autophagy, causes tumor cell death and inhibits cell proliferation.
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C5446646_NCI>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C5446646_NCI>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all